Literature DB >> 21537020

Identifying patients harboring extended-spectrum-beta-lactamase-producing Enterobacteriaceae on hospital admission: derivation and validation of a scoring system.

Mario Tumbarello1, Enrico Maria Trecarichi, Matteo Bassetti, Francesco Giuseppe De Rosa, Teresa Spanu, Eugenia Di Meco, Angela Raffaella Losito, Andrea Parisini, Nicole Pagani, Roberto Cauda.   

Abstract

Increases in community-acquired infections caused by extended-spectrum-β-lactamase (ESBL)-producing Enterobacteriaceae have important implications for hospital infection control and empirical antibiotic therapy protocols. We developed and validated a tool for identifying patients harboring these organisms at hospital admission. We retrospectively analyzed chart data for 849 adult inpatients. The derivation cohort included 339 patients admitted to a large hospital in Rome during 2008, with (n = 113) or without (n = 226) culture positivity for ESBL-producing Escherichia coli, Klebsiella spp., or Proteus mirabilis within 48 h after admission. Logistic-regression-based prediction scores were calculated based on variables independently associated with the outcome. The model was validated in a second cohort (n = 510) selected with identical criteria in hospitals in Genoa and Turin during 2009. Prediction scores were based on the following six variables (reported with odds ratio for study outcome and the 95% confidence intervals in brackets): recent (≤ 12 months before admission) hospitalization (5.69 [2.94 to 10.99]), transfer from another health care facility (5.61 [1.65 to 19.08]), Charlson comorbidity score ≥ 4 (3.80 [1.90 to 7.59]), recent (≤ 3 months before admission) β-lactam and/or fluoroquinolone treatment (3.68 [1.96 to 6.91]), recent urinary catheterization (3.52 [1.96 to 6.91]), and age ≥ 70 years (3.20 [1.79 to 5.70]). The model displayed good calibration and good-to-excellent discrimination in the derivation and validation sets (Hosmer-Lemshow χ(2) = 15.28 and 14.07; P = 0.17 and 0.23; areas under the receiver-operating characteristic curve, 0.83 and 0.92). It reliably identified patients likely to be harboring ESBL-producing Enterobacteriaceae at hospital admission who may need special infection control measures. Further study is needed to confirm this model's potential as a guide for prescribing empirical antibiotic therapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21537020      PMCID: PMC3122446          DOI: 10.1128/AAC.00009-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  34 in total

1.  Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis.

Authors:  Jesús Rodríguez-Baño; Encarnación Picón; Paloma Gijón; José Ramón Hernández; Maite Ruíz; Carmen Peña; Manuel Almela; Benito Almirante; Fabio Grill; Javier Colomina; Monserrat Giménez; Antonio Oliver; Juan Pablo Horcajada; Gemma Navarro; Ana Coloma; Alvaro Pascual
Journal:  Clin Infect Dis       Date:  2010-01-01       Impact factor: 9.079

2.  Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community- and hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrobial Resistance Trends (SMART).

Authors:  Stephen P Hawser; Samuel K Bouchillon; Daryl J Hoban; Robert E Badal; Rafael Cantón; Fernando Baquero
Journal:  Antimicrob Agents Chemother       Date:  2010-04-26       Impact factor: 5.191

Review 3.  Extended-spectrum beta-lactamase-producing organisms.

Authors:  M E Falagas; D E Karageorgopoulos
Journal:  J Hosp Infect       Date:  2009-07-10       Impact factor: 3.926

4.  Costs of bloodstream infections caused by Escherichia coli and influence of extended-spectrum-beta-lactamase production and inadequate initial antibiotic therapy.

Authors:  Mario Tumbarello; Teresa Spanu; Rossella Di Bidino; Marco Marchetti; Matteo Ruggeri; Enrico Maria Trecarichi; Gennaro De Pascale; Enrica Maria Proli; Roberto Cauda; Americo Cicchetti; Giovanni Fadda
Journal:  Antimicrob Agents Chemother       Date:  2010-07-26       Impact factor: 5.191

5.  Community-onset extended-spectrum beta-lactamase (ESBL) producing Escherichia coli: importance of international travel.

Authors:  Kevin B Laupland; Deirdre L Church; Jeanne Vidakovich; Melissa Mucenski; Johann D D Pitout
Journal:  J Infect       Date:  2008-11-05       Impact factor: 6.072

6.  A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients.

Authors:  Ronen Ben-Ami; Jesús Rodríguez-Baño; Hande Arslan; Johann D D Pitout; Claudine Quentin; Esther S Calbo; Ozlem K Azap; Corinne Arpin; Alvaro Pascual; David M Livermore; Javier Garau; Yehuda Carmeli
Journal:  Clin Infect Dis       Date:  2009-09-01       Impact factor: 9.079

7.  Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome.

Authors:  M Ortega; F Marco; A Soriano; M Almela; J A Martínez; A Muñoz; J Mensa
Journal:  J Antimicrob Chemother       Date:  2009-01-06       Impact factor: 5.790

8.  Risk factors for extended-spectrum beta-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections.

Authors:  O K Azap; H Arslan; K Serefhanoğlu; S Colakoğlu; H Erdoğan; F Timurkaynak; S S Senger
Journal:  Clin Microbiol Infect       Date:  2009-08-18       Impact factor: 8.067

9.  Prospective evaluation of colonization with extended-spectrum beta-lactamase (ESBL)-producing enterobacteriaceae among patients at hospital admission and of subsequent colonization with ESBL-producing enterobacteriaceae among patients during hospitalization.

Authors:  Reuven Friedmann; David Raveh; Esther Zartzer; Bernard Rudensky; Ellen Broide; Denise Attias; Amos M Yinnon
Journal:  Infect Control Hosp Epidemiol       Date:  2009-06       Impact factor: 3.254

10.  Clinical outcomes of spontaneous bacterial peritonitis due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species: a retrospective matched case-control study.

Authors:  Kyoung-Ho Song; Jae Hyun Jeon; Wan Beom Park; Sang-Won Park; Hong Bin Kim; Myoung-don Oh; Hyo-Suk Lee; Nam Joong Kim; Kang Won Choe
Journal:  BMC Infect Dis       Date:  2009-04-12       Impact factor: 3.090

View more
  42 in total

1.  Identifying patients harboring extended-spectrum-β-lactamase-producing Enterobacteriaceae on hospital admission is not that simple.

Authors:  Céline Slekovec; Xavier Bertrand; Joël Leroy; Jean-Pierre Faller; Daniel Talon; Didier Hocquet
Journal:  Antimicrob Agents Chemother       Date:  2012-04       Impact factor: 5.191

2.  Cumulative Effect of an Antimicrobial Stewardship and Rapid Diagnostic Testing Bundle on Early Streamlining of Antimicrobial Therapy in Gram-Negative Bloodstream Infections.

Authors:  P B Bookstaver; E B Nimmich; T J Smith; J A Justo; J Kohn; K L Hammer; C Troficanto; H A Albrecht; M N Al-Hasan
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

3.  Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum-β-lactamase-producing Enterobacteriaceae.

Authors:  Zaira Raquel Palacios-Baena; Belén Gutiérrez-Gutiérrez; Marina De Cueto; Pierluigi Viale; Mario Venditti; Alicia Hernández-Torres; Antonio Oliver; Luis Martínez-Martínez; Esther Calbo; Vicente Pintado; Oriol Gasch; Benito Almirante; José Antonio Lepe; Johann Pitout; Murat Akova; Carmen Peña-Miralles; Mitchell J Schwaber; Mario Tumbarello; Evelina Tacconelli; Julia Origüen; Nuria Prim; German Bou; Helen Giamarellou; Joaquín Bermejo; Axel Hamprecht; Federico Pérez; Manuel Almela; Warren Lowman; Po-Ren Hsueh; Carolina Navarro-San Francisco; Julián Torre-Cisneros; Yehuda Carmeli; Robert A Bonomo; David L Paterson; Álvaro Pascual; Jesús Rodríguez-Baño
Journal:  J Antimicrob Chemother       Date:  2017-03-01       Impact factor: 5.790

4.  Stratification of the impact of inappropriate empirical antimicrobial therapy for Gram-negative bloodstream infections by predicted prognosis.

Authors:  Sarah E Cain; Joseph Kohn; P Brandon Bookstaver; Helmut Albrecht; Majdi N Al-Hasan
Journal:  Antimicrob Agents Chemother       Date:  2014-10-27       Impact factor: 5.191

5.  Development of Institutional Guidelines for Management of Gram-Negative Bloodstream Infections: Incorporating Local Evidence.

Authors:  Elizabeth B Nimmich; P Brandon Bookstaver; Joseph Kohn; Julie Ann Justo; Katie L Hammer; Helmut Albrecht; Majdi N Al-Hasan
Journal:  Hosp Pharm       Date:  2017-07-21

6.  A Decision Tree Using Patient Characteristics to Predict Resistance to Commonly Used Broad-Spectrum Antibiotics in Children With Gram-Negative Bloodstream Infections.

Authors:  Anna C Sick-Samuels; Katherine E Goodman; Glenn Rapsinski; Elizabeth Colantouni; Aaron M Milstone; Andrew J Nowalk; Pranita D Tamma
Journal:  J Pediatric Infect Dis Soc       Date:  2020-04-30       Impact factor: 3.164

7.  Multidrug-resistant Proteus mirabilis bloodstream infections: risk factors and outcomes.

Authors:  Mario Tumbarello; Enrico Maria Trecarichi; Barbara Fiori; Angela Raffaella Losito; Tiziana D'Inzeo; Lara Campana; Alberto Ruggeri; Eugenia Di Meco; Elvira Liberto; Giovanni Fadda; Roberto Cauda; Teresa Spanu
Journal:  Antimicrob Agents Chemother       Date:  2012-03-26       Impact factor: 5.191

8.  European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia.

Authors:  Diana Averbuch; Christina Orasch; Catherine Cordonnier; David M Livermore; Malgorzata Mikulska; Claudio Viscoli; Inge C Gyssens; Winfried V Kern; Galina Klyasova; Oscar Marchetti; Dan Engelhard; Murat Akova
Journal:  Haematologica       Date:  2013-12       Impact factor: 9.941

Review 9.  Trends in human fecal carriage of extended-spectrum β-lactamases in the community: toward the globalization of CTX-M.

Authors:  Paul-Louis Woerther; Charles Burdet; Elisabeth Chachaty; Antoine Andremont
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

10.  Clinical and microbiological determinants of severe and fatal outcomes in patients infected with Enterobacteriaceae producing extended-spectrum β-lactamase.

Authors:  L Surgers; A Boyd; P-Y Boelle; V Lalande; P-A Jolivot; P-M Girard; G Arlet; C Cambier; A Homor; D Decre; J-L Meynard
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-02-08       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.